Linearis Labs offers metabolomics profiling services for biobanks using both a targeted 1300 metabolomic assay and untargeted LC-MS measurements. It is part of Linearis, which is building a combined omic/AI platform to identify signatures and accelerate drug development, screening, and monitoring in metabolomic diseases.
Focus Areas
Notable Investments
